Current treatment landscape for advanced hepatocellular carcinoma: Patient outcomes and the impact on quality of life

Daneng Li, Sabrina Sedano, Rebecca Allen, Jun Gong, May Cho, Sunil Sharma

    Research output: Contribution to journalReview article

    3 Citations (Scopus)

    Abstract

    Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.

    Original languageEnglish (US)
    Article number841
    JournalCancers
    Volume11
    Issue number6
    DOIs
    StatePublished - Jun 2019

    Fingerprint

    Hepatocellular Carcinoma
    Quality of Life
    Patient Care Management
    Therapeutics
    Second Primary Neoplasms
    Protein-Tyrosine Kinases
    Immunotherapy
    Decision Making
    Immunoglobulin G
    Monoclonal Antibodies
    Clinical Trials
    Physicians
    Mortality
    Population
    Neoplasms

    Keywords

    • Hepatocellular carcinoma
    • Quality of life
    • Systemic therapy

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Current treatment landscape for advanced hepatocellular carcinoma : Patient outcomes and the impact on quality of life. / Li, Daneng; Sedano, Sabrina; Allen, Rebecca; Gong, Jun; Cho, May; Sharma, Sunil.

    In: Cancers, Vol. 11, No. 6, 841, 06.2019.

    Research output: Contribution to journalReview article

    Li, Daneng ; Sedano, Sabrina ; Allen, Rebecca ; Gong, Jun ; Cho, May ; Sharma, Sunil. / Current treatment landscape for advanced hepatocellular carcinoma : Patient outcomes and the impact on quality of life. In: Cancers. 2019 ; Vol. 11, No. 6.
    @article{bd89ebcabd4f4a23b1288be6619f31e3,
    title = "Current treatment landscape for advanced hepatocellular carcinoma: Patient outcomes and the impact on quality of life",
    abstract = "Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.",
    keywords = "Hepatocellular carcinoma, Quality of life, Systemic therapy",
    author = "Daneng Li and Sabrina Sedano and Rebecca Allen and Jun Gong and May Cho and Sunil Sharma",
    year = "2019",
    month = "6",
    doi = "10.3390/cancers11060841",
    language = "English (US)",
    volume = "11",
    journal = "Cancers",
    issn = "2072-6694",
    publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
    number = "6",

    }

    TY - JOUR

    T1 - Current treatment landscape for advanced hepatocellular carcinoma

    T2 - Patient outcomes and the impact on quality of life

    AU - Li, Daneng

    AU - Sedano, Sabrina

    AU - Allen, Rebecca

    AU - Gong, Jun

    AU - Cho, May

    AU - Sharma, Sunil

    PY - 2019/6

    Y1 - 2019/6

    N2 - Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.

    AB - Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer mortality worldwide. Heterogeneity of clinical conditions contributes to the complex management of care for patients with advanced HCC. Recently, the treatment landscape for advanced HCC has expanded rapidly, with the additional FDA approvals of several oral tyrosine kinase inhibitors (lenvatinib, regorafenib, and cabozantinib), as well as immunotherapies such as immune check point inhibitors (nivolumab and pembrolizumab) and the monoclonal IgG1 antibody, ramucirumab. This expansion has generated a need for novel treatment sequencing strategies in this patient population. In light of these developments, an evaluation of the impact of FDA-approved therapeutics on patient-centered outcomes such as health-related quality of life (HRQoL) is warranted. An increased understanding of HRQoL in patients included in advanced HCC clinical trials could potentially help physician decision-making for treatment sequencing in patients with advanced HCC.

    KW - Hepatocellular carcinoma

    KW - Quality of life

    KW - Systemic therapy

    UR - http://www.scopus.com/inward/record.url?scp=85069640706&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85069640706&partnerID=8YFLogxK

    U2 - 10.3390/cancers11060841

    DO - 10.3390/cancers11060841

    M3 - Review article

    AN - SCOPUS:85069640706

    VL - 11

    JO - Cancers

    JF - Cancers

    SN - 2072-6694

    IS - 6

    M1 - 841

    ER -